Literature DB >> 15528366

Involvement of Fc gamma RI (CD64) in the mechanism of HIV-1 inhibition by polyclonal IgG purified from infected patients in cultured monocyte-derived macrophages.

Vincent Holl1, Stéphane Hemmerter, Renaud Burrer, Sylvie Schmidt, Alain Bohbot, Anne-Marie Aubertin, Christiane Moog.   

Abstract

The aim of this study was to investigate the mechanism of HIV-1 neutralization using monocyte-derived macrophages (MDM) in comparison to PBMC as target cells. For this purpose, we analyzed neutralizing activities of different human polyclonal IgG samples purified from sera of HIV-1-infected individuals using a single cycle infection assay. We found an increase of the neutralizing titer when macrophages vs PBMC were used as target cells. Moreover, polyclonal IgG from HIV-1-infected patients that are not able to neutralize virus when PBMC are used as target cells strongly inhibit MDM infection. Similar results were obtained with neutralizing mAbs. To explore the participation of FcgammaRs in HIV-1 inhibition, F(ab')(2) and Fab of these Igs were produced. Results indicated that both F(ab')(2) and Fab are less effective to inhibit virus replication in MDM. Moreover, competition experiments with Fc fragments of IgG from healthy donors or with purified monoclonal anti-human FcgammaRs Ab strengthen the participation of the FcgammaRs, and in particular of FcgammaRI (CD64) in HIV-1 inhibition on MDM. Mechanisms by which HIV-specific IgG inhibit virus replication in cultured macrophages are proposed and the benefit of inducing such Abs by vaccination is discussed.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15528366     DOI: 10.4049/jimmunol.173.10.6274

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  40 in total

1.  Rhesus macaque polyclonal and monoclonal antibodies inhibit simian immunodeficiency virus in the presence of human or autologous rhesus effector cells.

Authors:  Donald N Forthal; Gary Landucci; Kelly Stefano Cole; Marta Marthas; Juan C Becerra; Koen Van Rompay
Journal:  J Virol       Date:  2006-09       Impact factor: 5.103

2.  Nonneutralizing antibodies are able to inhibit human immunodeficiency virus type 1 replication in macrophages and immature dendritic cells.

Authors:  Vincent Holl; Maryse Peressin; Thomas Decoville; Sylvie Schmidt; Susan Zolla-Pazner; Anne-Marie Aubertin; Christiane Moog
Journal:  J Virol       Date:  2006-06       Impact factor: 5.103

3.  Efficient inhibition of HIV-1 replication in human immature monocyte-derived dendritic cells by purified anti-HIV-1 IgG without induction of maturation.

Authors:  Vincent Holl; Maryse Peressin; Sylvie Schmidt; Thomas Decoville; Susan Zolla-Pazner; Anne-Marie Aubertin; Christiane Moog
Journal:  Blood       Date:  2006-02-09       Impact factor: 22.113

4.  Single-chain protein mimetics of the N-terminal heptad-repeat region of gp41 with potential as anti-HIV-1 drugs.

Authors:  Sara Crespillo; Ana Cámara-Artigas; Salvador Casares; Bertrand Morel; Eva S Cobos; Pedro L Mateo; Nicolas Mouz; Christophe E Martin; Marie G Roger; Raphaelle El Habib; Bin Su; Christiane Moog; Francisco Conejero-Lara
Journal:  Proc Natl Acad Sci U S A       Date:  2014-12-08       Impact factor: 11.205

5.  A new lease on life for an HIV-neutralizing antibody class and vaccine target.

Authors:  Dennis R Burton
Journal:  Proc Natl Acad Sci U S A       Date:  2021-02-16       Impact factor: 11.205

6.  Enhanced phagocytic activity of HIV-specific antibodies correlates with natural production of immunoglobulins with skewed affinity for FcγR2a and FcγR2b.

Authors:  Margaret E Ackerman; Anne-Sophie Dugast; Elizabeth G McAndrew; Stephen Tsoukas; Anna F Licht; Darrell J Irvine; Galit Alter
Journal:  J Virol       Date:  2013-03-06       Impact factor: 5.103

Review 7.  Role of Fc-mediated antibody function in protective immunity against HIV-1.

Authors:  George K Lewis
Journal:  Immunology       Date:  2014-05       Impact factor: 7.397

8.  Decreased Fc receptor expression on innate immune cells is associated with impaired antibody-mediated cellular phagocytic activity in chronically HIV-1 infected individuals.

Authors:  Anne-Sophie Dugast; Andrew Tonelli; Christoph T Berger; Margaret E Ackerman; Gaia Sciaranghella; Qingquan Liu; Magdalena Sips; Ildiko Toth; Alicja Piechocka-Trocha; Musie Ghebremichael; Galit Alter
Journal:  Virology       Date:  2011-05-12       Impact factor: 3.616

9.  Non-neutralizing antibody functions for protection and control HIV in humans and SIV and SHIV in non-human primates.

Authors:  Susan Zolla-Pazner
Journal:  AIDS       Date:  2016-10-23       Impact factor: 4.177

10.  Heterologous Prime-Boost HIV-1 Vaccination Regimens in Pre-Clinical and Clinical Trials.

Authors:  Scott A Brown; Sherri L Surman; Robert Sealy; Bart G Jones; Karen S Slobod; Kristen Branum; Timothy D Lockey; Nanna Howlett; Pamela Freiden; Patricia Flynn; Julia L Hurwitz
Journal:  Viruses       Date:  2010-02-01       Impact factor: 5.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.